It’s an Exciting Moment for Telecommunication Infrastructure Growth


It’s an exciting moment for the growth of telecommunication infrastructure, especially in places that aren’t New York City or Los Angeles.

While the “big three” companies will continue to fight each other in urban markets, rolling out things like 5G and battling for the best densification, there’s enormous space for the hundreds of smaller companies who are looking to serve small towns and rural environments, which became even more attractive in 2020.

“The new race is the rural race. That’s where the Tier 2s, the Tier 3s, the munis, the co-ops and the electric utilities are really playing a role,” said Tom Counts, CEO of 3-GIS. “The electric utilities have a number of factors pushing them. They’ve seen declining revenue for the last decade. They’ve been looking at, ‘How do I do revenue replacement?’ But at the same time, boom, you’ve got (Rural Digital Opportunity Fund) funding that’s come out and COVID hitting everyone, and people have run to the woods. They’re sheltering in place, working from home and the race to be able to successfully allow them to do that is on, and it is on big time.

“With SSP, who has a fantastic reputation and position all across the utility space, we are finally going to be well-prepared to answer that call.”

SSP had long been hoping to work with a company like 3-GIS, though CEO Skye Perry joked that Counts at first ignored his calls.

“As we’ve grown we were primarily a service provider,” Perry said. “What we saw when we looked at 3-GIS is they come from the opposite direction as far as product-first. They’re a completely product-oriented business. They certainly do services, too, with their products, but they’ve really focused on not getting into the customization business, which is a tremendous move for a product provider.

“As we bring these (organizations) together with their complementary backgrounds and offering, as I go through and sort of articulate the synergistic opportunities between us, that probably gets me just as excited as anything. We do different things, but when we bring it together, we’re going to do all of it a whole lot better.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More